Option chain shows key data for Theriva Biologics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Theriva Biologics.

Theriva Biologics (AMEX:TOVX) Stock, Option Chain

Theriva Biologics

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Stuttgart,,Germany,-,10-03-2022:,Mobile,Phone,With,Logo,Of,American

News

Downgrades

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

AXTA

COTY

MCRB

TOVX

This Coty Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Thursday

Wall Street

Equities

Futures

Economics

Federal Reserve

ETFs

AVGR

CREV

NEUE

NVDA

TIVC

TSLA

U.S. stock futures advanced on Tuesday, head of a shortened trading session owning to Christmas-eve. The stock market will shut at 1 p.m. ET.

US Stocks To Open Higher On Shortened Trading Day: Santa Claus Rally Period Officially Begins, Says Analyst

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Movers

AMPG

BIPC

CHEK

FDSB

HSDT

KORE

LAES

LIND

NCRA

NVNI

RELI

SLGL

TLRY

Why Carbon Revolution Shares Are Trading Higher By Around 62%; Here Are 20 Stocks Moving Premarket

Theriva Biologics Inc

Earnings

Press Releases

Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results

Health Care

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

General

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Theriva™ Biologics Announces Positive Outcomes from the Second Meeting of the Independent Data Monitoring Committee for VIRAGE, the Company's Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Theriva™ Biologics Announces Primary Endpoints for Efficacy and Safety Achieved in VIRAGE Phase 2b Clinical Trial of VCN-01 with Gemcitabine/nab-Paclitaxel in Newly-Diagnosed Metastatic Pancreatic Cancer Patients

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

Financing

Theriva Biologics Announces Closing of $7.5 Million Public Offering

Aditxt

Apollomics

Aptevo Therapeutics

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Bone Biologics

Entero Therapeutics

Genprex

GRI Bio

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics

NuCana

Onconetix

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics

Screenshot 2024-08-23 at 5.34.20 PM

Biotech

Theriva Biologics Receives Rare Pediatric Drug Designation From FDA For Treatment Of Retinoblastoma

Screenshot 2024-07-31 at 5.25.33 PM

Theriva Biologics Advances Its Product Pipeline To Improve Survival Rates For Many Difficult-To-Treat Cancers

Screenshot 2024-07-08 at 2.14.39 PM

Disproportionate Rise In Pancreatic Cancer Among Young Women Highlights High Unmet Need To Find Safe, Effective Treatments – Is Hope On The Horizon?

Screenshot 2024-06-06 at 5.27.01 PM

Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic Cancer

Screenshot 2024-04-16 at 5.31.31 PM

Theriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat Cancers

Screenshot 2024-03-26 at 11.16.22 PM

Utilizing Common Viruses To Combat Dangerous Cancers – Hear From The Leaders Of This Biotech

Screenshot 2024-03-13 at 5.34.18 PM

How Theriva Biologics Is Using An Adenovirus To Develop A Novel Treatment For Pancreatic Cancer, As Well As Other Cancers With An Unmet Need

Screenshot 2024-03-05 at 6.31.45 PM

CADL

CGON

CLDI

Could This Common Virus Unlock New Cancer Treatments? Theriva Biologics Believes That Adenoviruses Could Be Instrumental In The Next Evolution Of Oncology

Screenshot 2024-02-28 at 6.54.06 PM

For The First Time The US Is Set To Hit 2 Million New Cancer Cases: Theriva Biologics Presents Novel Solutions To The Deadliest Cancers

Comments

Theriva Biologics

Theriva Biologics (TOVX) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell